Pilot Study of Rosuvastatin and Enoxaparin Thromboprophylaxis Following Ovarian Cancer Surgery (O-STAT Study)

Model scores of the 29,894 trials active now.

Model score 25% for any early termination, 16% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 26% of the time (3,728 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2024-05-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: cancerinstitutionalsurgeryreceivingprior to
  Phrases that lowered it: participantsallergicbleedingjapanesehistory
• Sponsor's past termination rate: 15.6% (raises risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 2 (raises risk) · Design
• Primary purpose: prevention (lowers risk) · Design
• Disease area, cancer: Yes (raises risk) · Disease area
• Collaborators: 2 (lowers risk) · Design
• Design: parallel (raises risk) · Design
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Has a data monitoring committee: Yes (raises risk) · Design
• Trials the sponsor started in the prior 2 years: 39 (lowers risk) · Sponsor's track record
• Drug's FAERS reports with a death: 8.9% (lowers risk) · Drug's FDA history
• Minimum age: 18 (raises risk) · Who can join
• Sponsor's past trials: 173 (lowers risk) · Sponsor's track record
• Drug's FAERS reports marked serious: 71.1% (lowers risk) · Drug's FDA history
• Drug's FAERS reports in the prior 12 months: 18314 (lowers risk) · Drug's FDA history
• Number of arms: 3 (lowers risk) · Design
• Blinding: none (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Detecting the Impact of Statin Therapy On Lowering Risk of Venous Thrombo-Embolic Events (DISOLVE) NCT01524653 · started 2012 · scored riskier than 28% of active trials completed
• Characterization of Multi-dose RVX000222 in Combination With Statin Treatment in Dyslipidemia NCT01863225 · started 2013 · scored riskier than 22% of active trials terminated
• Rosuvastatin in Treating Patients With Stage I or Stage II Colon Cancer That Was Removed By Surgery NCT01011478 · started 2010 · scored riskier than 64% of active trials terminated
• A Repeat Dose Study to Investigate the Interaction of GSK2190915 on the Pharmacokinetics of Rosuvastatin NCT01411111 · started 2011 · scored riskier than 3% of active trials completed
• Combined Effects of Non-statin Treatments on Apolipoprotein A-I Up-Regulation (CENTAUR): A Feasibility Study NCT00728910 · started 2008 · scored riskier than 40% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.